CELC Trading Analysis - 10/09/2026 10:55 AM — TRU-SENTIMENT

News Headlines & Context

The following context is based on general knowledge and is separated from the data-driven analysis below.

• Cellularity (CELC) has faced sustained pressure across the biotech sector as investors rotated out of speculative clinical-stage names amid rising rate concerns in late 2026.
• Recent pipeline updates from CELC's lead cell-therapy programs showed mixed interim data, contributing to a sharp drawdown from summer highs near $98.00.
• No near-term earnings catalyst is scheduled before the next major options expiration (2026-11-20), leaving technical and options flow as primary drivers.
• Broader sector weakness and a high-beta profile (β = 1.36) have amplified CELC's declines relative to the broader market.
• Context: The headlines align with the embedded data showing a falling price structure, bearish options conviction, and deeply negative momentum.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for CELC:

• Trailing EPS is -4.30, confirming the company is not profitable at the trailing twelve-month level.
• Trailing P/E, forward P/E, PEG ratio, price-to-book, profit margins, ROE, and debt-to-equity are all null/unavailable — no positive valuation anchor exists in the data.
• Revenue growth, total revenue, and free cash flow are null; fundamental trend cannot be assessed from supplied data.
• Market cap is $3.33B with 48.93M shares outstanding; 52-week range is $45.03 to $151.02, with current price (~$67.63) near the lower third of that range.
• Institutional ownership is 39.61%, average volume 1.30M, historical volatility 51.83%, beta 1.36 (highly volatile, high-market-sensitivity).
• Analyst consensus, target mean price, and recommendation key are null — no external rating context provided.
• Fundamentals (negative EPS, no profitability metrics) align with the bearish technical and sentiment picture in the embedded data.

Current Market Position

Current price per indicators: $67.63 (as of 2026-10-08 close). Minute bars show 2026-10-08 open $64.74, high $65.86, low $64.50, close $65.67 early session; by 2026-10-09 10:25 price traded $67.85 after dipping to $67.42. Last 5 minute bars indicate mild intraday recovery from $67.42 to $67.85 on volume of 29,971 (10:25 bar).

Daily history shows a decline from $93.24 (2026-08-27) to $67.63 (2026-10-08), with 30-day low $63.23 and high $98.00. Recent daily closes: 2026-10-07 $65.98, 2026-10-08 $67.63 — a modest 2.5% bounce.

Technical Analysis

Price is below all major SMAs (5/20/50) in bearish alignment, no bullish crossover present. RSI 30.71 indicates oversold-but-not-extreme weakness. MACD (-5.13) below signal (-4.10), histogram -1.03 confirms bearish momentum. Price sits just above Bollinger lower band ($67.45), near lower band expansion. 30-day range: price at $67.63 is 8.2% above 30-day low, 31.0% below 30-day high.

True Sentiment Analysis (Delta 40-60 Options)

Based on embedded TRUE SENTIMENT OPTIONS data:

Call Volume: $0.00 (0.0%) Put Volume: $28,600.00 (100.0%) Total: $28,600.00

• Sentiment flagged Bearish with 0 call contracts, 11 put contracts, 1 put trade.
• Pure directional conviction shows 100% put dollar volume — unambiguous bearish positioning in delta 40-60 filter.
• Suggests near-term expectations of continued downside or protective hedging into 2026-11-20.
• No divergence from technicals: both price structure and options flow agree on bearish bias.

Key Price Levels (Observational Only)